Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Unicycive Therapeutics In...

    NASDAQ: UNCY · Real-Time Price · USD
    0.75
    0.07 (10.07%)
    At close: Jun 16, 2025, 3:59 PM
    0.74
    -0.55%
    Pre-market: Jun 17, 2025, 07:03 AM EDT

    Unicycive Therapeutics Statistics

    Share Statistics

    Unicycive Therapeutics has 120.63M shares outstanding. The number of shares has increased by 176% in one year.

    Shares Outstanding

    n/a
    		 120.63M

    Shares Change (YoY)

    n/a
    		 176%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 69.37%

    Shares Floating

    n/a
    		 100.03M

    Failed to Deliver (FTD) Shares

    n/a
    		 18,571

    FTD / Avg. Volume

    n/a
    		 0.69%

    Short Selling Information

    The latest short interest is 356.9K, so 0.3% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 356.9K

    Short % of Shares Out

    n/a
    		 0.3%

    Short % of Float

    n/a
    		 0.31%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -14.48 and the forward PE ratio is 0.37. Unicycive Therapeutics's PEG ratio is 0.15.

    PE Ratio

    n/a
    		 -14.48

    Forward PE

    n/a
    		 0.37

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 71.59

    P/FCF Ratio

    n/a
    		 -18.57

    PEG Ratio

    n/a
    		 0.15
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Unicycive Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.1.

    Current Ratio

    n/a
    		 1.28

    Quick Ratio

    n/a
    		 1.28

    Debt / Equity

    n/a
    		 0.1

    Debt / EBITDA

    n/a
    		 -0.02

    Debt / FCF

    n/a
    		 -0.03

    Interest Coverage

    n/a
    		 -452.35

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,669,500

    Employee Count

    n/a
    		 22

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -1.09M

    Effective Tax Rate

    n/a
    		 2.89%

    Stock Price Statistics

    The stock price has increased by 15.33% in the last 52 weeks. The beta is 2, so Unicycive Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2

    52-Week Price Change

    n/a
    		 15.33%

    50-Day Moving Average

    n/a
    		 0.62

    200-Day Moving Average

    n/a
    		 0.57

    Relative Strength Index (RSI)

    n/a
    		 56.46

    Average Volume (20 Days)

    n/a
    		 2,692,466

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -32.12M

    Net Income

    n/a
    		 -36.73M

    EBITDA

    n/a
    		 -36.23M

    EBIT

    n/a
    		 -37.9M

    Earnings Per Share (EPS)

    n/a
    		 -0.06
    Full Income Statement

    Balance Sheet

    The company has 26.14M in cash and 773K in debt, giving a net cash position of 25.37M.

    Cash & Cash Equivalents

    n/a
    		 26.14M

    Total Debt

    n/a
    		 773K

    Net Cash

    n/a
    		 25.37M

    Retained Earnings

    n/a
    		 -101.27M

    Total Assets

    n/a
    		 27.95M

    Working Capital

    n/a
    		 10.67M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -28.57M and capital expenditures -72K, giving a free cash flow of -28.65M.

    Operating Cash Flow

    n/a
    		 -28.57M

    Capital Expenditures

    n/a
    		 -72K

    Free Cash Flow

    n/a
    		 -28.65M

    FCF Per Share

    n/a
    		 -0.04
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    UNCY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for UNCY is $6, which is 700% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6

    Price Target Difference

    n/a
    		 700%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -6.86

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist